Why was the Ionis share sale described as automatic for Holly Kordasiewicz?

The filing states the 4,141-share sale was an automatic sale made to cover required tax withholding obligations under the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice.

Ionis Pharmaceuticals (IONS) EVP reports RSU vesting and tax sale

Q: How many Ionis common shares did Holly Kordasiewicz sell and at what price?

On 01/16/2026 , Holly Kordasiewicz sold 4,141 shares of Ionis common stock at a weighted average price of $75.66 per share, in multiple trades between $75.63 and $75.72, to cover required tax withholding.

Q: How many Ionis shares did Holly Kordasiewicz acquire through RSU vesting?

On 01/15/2026 , she acquired 11,119 shares of Ionis common stock at $0.0 per share, pursuant to the vesting and release of previously granted restricted stock units.

Q: What new restricted stock unit awards did Holly Kordasiewicz receive from Ionis?

On 01/15/2026 , she received two new RSU awards: one for 13,650 units and another for 11,250 units, both at an exercise price of $0.0 per unit, raising her total RSU holdings to 45,730 units.

Q: How do Holly Kordasiewicz’s Ionis RSUs vest and settle?

The restricted stock units vest in four equal annual installments . Upon vesting, they are paid out in whole shares of Ionis common stock or in cash, as determined by the company. Each RSU represents the right to receive one share of Ionis common stock or its equivalent cash value.

Filing Impact

(Moderate)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

Ionis Pharmaceuticals executive Holly B. Kordasiewicz, EVP and Chief Development Officer, reported multiple equity transactions. On 01/15/2026, 11,119 shares of common stock were acquired at $0.0 per share through the vesting and release of previously granted restricted stock units. On 01/16/2026, 4,141 shares were sold at a weighted average price of $75.66 per share in an automatic sale to cover tax withholding obligations under the company’s equity incentive plan, leaving 14,718 common shares directly owned.

On the derivative side, restricted stock units were exercised or granted at $0.0 per unit on 01/15/2026. An RSU conversion of 11,119 units reduced the RSU balance to 20,830 units. Additional grants of 13,650 and 11,250 RSUs increased the total RSU holdings to 45,730 units. Each RSU represents the right to receive one share of Ionis common stock or its cash equivalent, vesting in four equal annual installments.

Insider Trade Summary

Net Seller: 4,141 shares ($313,308)

Net Sell 5 txns

Insider Kordasiewicz Holly B.

Role EVP, Chief Development Officer

Sold 4,141 shs ($313K)

Type	Security	Shares	Price	Value
Sale	Common Stock	4,141	$75.66	$313K
Exercise	Restricted Stock Unit	11,119	$0.00	--
Grant/Award	Restricted Stock Unit	13,650	$0.00	--
Grant/Award	Restricted Stock Unit	11,250	$0.00	--
Exercise	Common Stock	11,119	$0.00	--

Holdings After Transaction: Common Stock — 14,718 shares (Direct); Restricted Stock Unit — 20,830 shares (Direct)

Footnotes (1)

Acquired pursuant to vesting and release of shares in accordance with Restricted Stock Unit awards. The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.63 to $75.72 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) on this Form 4. Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value. Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. Grant to reporting person of Restricted Stock Units under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan.

Form 4 Insider Transactions: What Each Field Means →

01/20/2026 - 08:18 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kordasiewicz Holly B.

(Last)

(First)

(Middle)

2855 GAZELLE COURT

(Street)

CARLSBAD

92010

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
IONIS PHARMACEUTICALS INC [ IONS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	EVP, Chief Development Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/15/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	01/15/2026		M⁽¹⁾		11,119⁽¹⁾	A	$0.0	18,859	D
Common Stock	01/16/2026		S⁽²⁾		4,141⁽²⁾	D	$75.66⁽³⁾	14,718	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Restricted Stock Unit	$0.0⁽⁴⁾	01/15/2026		M			11,119	01/15/2026⁽⁵⁾	⁽⁵⁾	Common Stock	11,119	$0.0	20,830	D
Restricted Stock Unit⁽⁶⁾	$0.0⁽⁴⁾	01/15/2026		A		13,650		01/15/2027⁽⁵⁾	⁽⁵⁾	Common Stock	13,650	$0.0	34,480	D
Restricted Stock Unit⁽⁶⁾	$0.0⁽⁴⁾	01/15/2026		A		11,250		01/15/2027⁽⁵⁾	⁽⁵⁾	Common Stock	11,250	$0.0	45,730	D

Explanation of Responses:

1. Acquired pursuant to vesting and release of shares in accordance with Restricted Stock Unit awards.

2. The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice.

3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.63 to $75.72 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) on this Form 4.

4. Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.

5. Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company.

6. Grant to reporting person of Restricted Stock Units under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan.

	By: Patrick R. O'Neil, attorney-in-fact For: Holly Kordasiewicz	01/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Ionis (IONS) executive Holly Kordasiewicz report?

Holly B. Kordasiewicz, EVP and Chief Development Officer of Ionis Pharmaceuticals, reported a mix of stock acquisitions from restricted stock unit (RSU) vesting, new RSU grants, and a sale of shares to cover tax withholding obligations.

How many Ionis common shares did Holly Kordasiewicz sell and at what price?

On 01/16/2026, Holly Kordasiewicz sold 4,141 shares of Ionis common stock at a weighted average price of $75.66 per share, in multiple trades between $75.63 and $75.72, to cover required tax withholding.

How many Ionis shares did Holly Kordasiewicz acquire through RSU vesting?

On 01/15/2026, she acquired 11,119 shares of Ionis common stock at $0.0 per share, pursuant to the vesting and release of previously granted restricted stock units.

What is Holly Kordasiewicz’s Ionis common stock holding after these transactions?

Following the reported transactions, Holly Kordasiewicz directly owned 14,718 shares of Ionis common stock.

What new restricted stock unit awards did Holly Kordasiewicz receive from Ionis?

On 01/15/2026, she received two new RSU awards: one for 13,650 units and another for 11,250 units, both at an exercise price of $0.0 per unit, raising her total RSU holdings to 45,730 units.

How do Holly Kordasiewicz’s Ionis RSUs vest and settle?

The restricted stock units vest in four equal annual installments. Upon vesting, they are paid out in whole shares of Ionis common stock or in cash, as determined by the company. Each RSU represents the right to receive one share of Ionis common stock or its equivalent cash value.